Auxilium Pharmaceuticals (Nasdaq: AUXL) reported earnings on Nov. 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Auxilium Pharmaceuticals whiffed on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP loss per share grew.

Margins dropped across the board.

Revenue details
 Auxilium Pharmaceuticals booked revenue of $71.0 million. The 13 analysts polled by S&P Capital IQ hoped for sales of $79.5 million on the same basis. GAAP reported sales were 6.4% higher than the prior-year quarter's $66.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.21. The 12 earnings estimates compiled by S&P Capital IQ anticipated -$0.07 per share. GAAP EPS were -$0.21 for Q3 against -$0.08 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 77.7%, 200 basis points worse than the prior-year quarter. Operating margin was -15.1%, 880 basis points worse than the prior-year quarter. Net margin was -14.8%, 870 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $87.2 million. On the bottom line, the average EPS estimate is -$0.06.

Next year's average estimate for revenue is $322.5 million. The average EPS estimate is -$0.04.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 123 members out of 178 rating the stock outperform, and 55 members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Auxilium Pharmaceuticals a green thumbs-up, and 26 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $26.18.